This Article Full Text (OnlineFirst[PDF]) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Google Scholar Articles by Chen, J. P. Articles by King, S. PubMed PubMed Citation Articles by Chen, J. P. Articles by King, S. Social Bookmarking                   What's this?

Late Angiographic Stent Thrombosis: The LAST Straw for Drug-Eluting Stents?

^* To whom correspondence should be addressed. E-mail: chenjackapollo{at}yahoo.com.

	Abstract

The long-term patency advantage of drug-eluting stents represents a quantum leap in the percutaneous treatment of ischemic heart disease. Although initial landmark trials demonstrated equivalent safety to bare-metal stents, subsequent follow-up analyses have suggested a slight late thrombotic risk. This widely publicized issue poses major public health implications for the medical and lay communities. However, available data indicate that this late risk is counterbalanced by the dramatic drug-eluting stent reduction in target lesion revascularizations, resulting in equivalent overall major adverse cardiovascular event rates than that of the bare-metal stents The recent Food and Drug Administration’s guidelines regarding these devices are delineated in detail. Specifically, compliance with dual antiplatelet therapy (minimum 1 year) is of paramount consideration in patient selection for drug-eluting stents. Moreover, when deployed for "on-label" indications, they provide significant restenosis advantage, with a slight late thrombotic risk but without overall increase in death or infarction.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?